Sinovac Research And Development Co Ltd

Country

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

Phase 1

Active, not recruiting

Conditions: Pneumococcal Infectious Disease

Interventions: Biological: PREVNAR 13
Biological: Sinovac PCV13

First Posted Date: 2023-12-27

Last Posted Date: 2025-04-17

Lead Sponsor: Sinovac Research and Development Co., Ltd.

Target Recruit Count: 140

Registration Number: NCT06183216

Locations: 🇨🇳
Binchuan County Center for Diseases Control and Prevention, Dali, Yunnan, China

Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above

Phase 3

Completed

Conditions: COVID-19

Interventions: Biological: COVID-19 Vaccine (Vero cell), Inactivated (CZ strain)
Biological: COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant)

First Posted Date: 2022-05-19

Last Posted Date: 2024-05-31

Lead Sponsor: Sinovac Research and Development Co., Ltd.

Target Recruit Count: 1750

Registration Number: NCT05381350

Locations: 🇨🇳
Huaiyin Center for Disease Control and Prevention, Huai'an, Jiangsu, China

Effectiveness of Inactivated COVID-19 Vaccine of the First Booster Dose

Conditions: COVID-19

Interventions: Biological: COVID-19 Vaccine (Vero Cell), Inactivated

First Posted Date: 2022-05-10

Last Posted Date: 2023-01-12

Lead Sponsor: Sinovac Research and Development Co., Ltd.

Target Recruit Count: 14000

Registration Number: NCT05367895

Locations: 🇧🇷
Instituto Nacional de Infectologia Evandro Chagas (INI-FIOCRUZ), Manguinhos, Brazil

Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated Vaccine in Healthy Adults in in Hong Kong

Phase 2

Withdrawn

Conditions: COVID-19

Interventions: Biological: COVID-19 Vaccine (Vero Cell), Inactivated (Medium-dose)
Biological: COVID-19 Vaccine (Vero Cell), Inactivated (High-dose)

First Posted Date: 2022-02-24

Last Posted Date: 2023-09-22

Lead Sponsor: Sinovac Research and Development Co., Ltd.

Registration Number: NCT05254236

Locations: 🇨🇳
Gleneagles Hospital HongKong, Hong Kong, China

Immunogenicity of an Inactivated COVID-19 Vaccine

Phase 4

Completed

Conditions: COVID-19

Interventions: Biological: Inactivated COVID-19 Vaccine

First Posted Date: 2022-01-20

Last Posted Date: 2023-09-25

Lead Sponsor: Sinovac Research and Development Co., Ltd.

Target Recruit Count: 395

Registration Number: NCT05198336

Locations: 🇨🇳
Rushan City Center for Disease Control and Prevention, Weihai, Shandong, China

Safety and Immunogenicity Study of Booster Vaccination With COVID-19 Vaccine (Vero Cell),Inactivated From Different Manufactures for Prevention of COVID-19

Phase 4

Suspended

Conditions: COVID-19

Interventions: Biological: Experimental vaccine 2
Biological: Experimental vaccine 1
Biological: Experimental vaccine 3

First Posted Date: 2021-12-21

Last Posted Date: 2022-08-11

Lead Sponsor: Sinovac Research and Development Co., Ltd.

Target Recruit Count: 480

Registration Number: NCT05165732

Locations: 🇨🇳
Yanhe Tujia Autonomous County Center for Disease Control and Prevention, Tongren, Guizhou, China

Efficacy,Immunogenicity and Safety of COVID-19 Vaccine , Inactivated Booster Dose in Adults Aged 18 Years and Above

Phase 3

Withdrawn

Conditions: COVID-19

Interventions: Biological: High-dosage COVID-19 Vaccine,Inactivated
Biological: Placebo-comparator group
Biological: Medium-dosage COVID-19 Vaccine,Inactivated

First Posted Date: 2021-12-14

Last Posted Date: 2023-02-08

Lead Sponsor: Sinovac Research and Development Co., Ltd.

Registration Number: NCT05156632

Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in Turkey

Phase 2

Suspended

Conditions: COVID-19

Interventions: Biological: Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated
Biological: High-dose COVID-19 Vaccine(Vero Cell),Inactivated

First Posted Date: 2021-12-09

Last Posted Date: 2022-08-11

Lead Sponsor: Sinovac Research and Development Co., Ltd.

Target Recruit Count: 640

Registration Number: NCT05150496

Locations: 🇹🇷
Republic of Turkey Ministry of Health Ankara City Hospital Department of Internal Diseases, Ankara, Turkey
🇹🇷
Hacettepe University Faculty of Medicine, Department of Internal Diseases / Infectious Diseases and Clinical Microbiology Unit, Ankara, Turkey

Safety and Immunogenicity of COVID-19 Vaccine, Inactivated in Healthy Population Aged From 3 to 11 Years

Phase 3

Completed

Conditions: COVID-19

Interventions: Biological: COVID-19 Vaccine,Inactivated

First Posted Date: 2021-11-30

Last Posted Date: 2023-10-16

Lead Sponsor: Sinovac Research and Development Co., Ltd.

Target Recruit Count: 1000

Registration Number: NCT05137418

Locations: 🇨🇳
Sheyang County Center for Disease Control and Prevention, Yancheng, Jiangsu, China

Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 Years

Phase 4

Active, not recruiting

Conditions: COVID-19

Interventions: Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 3
Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 3
Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 2
Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 2
Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 3
Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2
Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 1

First Posted Date: 2021-11-09

Last Posted Date: 2023-11-07

Lead Sponsor: Sinovac Research and Development Co., Ltd.

Target Recruit Count: 2520

Registration Number: NCT05112913

Locations: 🇨🇳
Yaliang county Center for Disease Control and Prevention, Xi'an, Shanxi, China

Home Terms & Conditions Privacy Policy